This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
He provides a fascinating glimpse into what it takes to excel in the field of medical device sales, emphasizing the importance of authenticity and passion. The perfect blend of persistent dedication, a heartwarming touch of southern hospitality, and an innate understanding of the needs of both physicians and patients.
GlobalData predicts Bristol-Myers Squibb’s Breyanzi and Gilead’s Yescarta are set to have high annual sales in the forecast period. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Peak sales are anticipated to reach $1.3 billion in 2031.
Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. After this period, CMS will begin to include physician-administered drugs covered under Part B in the program.
We look forward to introducing physicians to the SavvyWire at the upcoming TCT meeting in Boston later this week and then initiating our limited market release of the product to a select number of physician thought-leaders during the coming weeks,” concluded Mr. Laflamme. About OpSens Inc. www.OpSens.com or www.OpSensmedical.com ).
The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.
The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.
BN by 2027. He is a former assistant team physician to The Cleveland Guardians and Cleveland Cavaliers. The company has raised more than $18 million to date from institutional investors, family offices, and more than 50 physician champions. This system has helped propel the arthroscopic market to an expected US $16.3
and ramped up sales of PFA systems in Europe. Based on brisk uptake in the latter half of the first quarter, it appeared that PFA would account for at least 30% of the ablation market and $1 billion in sales by the end of 2024. Since the FDA’s approval of the first pulsed field ablation (PFA) system in the U.S. s Farapulse.
Pharma, formulary decision-makers, and contracting specialists must now track exact dates when drugs became available, then track the difference between average sales price (ASP) and Maximum Fair Price (MFP) to ensure provider reimbursement is correct.”
By 2025, sales of consumer health products are expected to reach $368bn, according to Euromonitor, encompassing everything from sleep aids to vitamins to sports nutrition products. markets by 2025 and 1,000 by 2027—and more than half of those practices are expected to be in medically underserved communities.
GoodRx is the leading platform 2 with the highest unaided awareness and trust across patients, physicians, and pharmacists 3 that Americans—regardless of insurance status—use across many phases of their healthcare journey. The Uses—and Costs—of Specialty Treatments Keep Rising A U.S.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content